California State Teachers Retirement System Sells 110 Shares of Charles River Laboratories International, Inc. $CRL

California State Teachers Retirement System reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 0.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,862 shares of the medical research company's stock after selling 110 shares during the quarter. California State Teachers Retirement System owned 0.12% of Charles River Laboratories International worth $12,895,733 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company's stock worth $254,186,000 after acquiring an additional 9,756 shares during the last quarter. Bank of America Corp DE increased its holdings in Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock valued at $195,792,000 after buying an additional 54,500 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Charles River Laboratories International by 8.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company's stock worth $166,813,000 after buying an additional 66,803 shares during the last quarter. Finally, Amundi lifted its holdings in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after buying an additional 492,301 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CRL shares. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Mizuho set a $264.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Barclays restated an "overweight" rating and set a $300.00 price target on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Weiss Ratings upgraded shares of Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 1st. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $265.69.

Charles River Laboratories International Trading Up 0.7%

Charles River Laboratories International stock traded up $2.04 during trading on Tuesday, hitting $275.15. The company's stock had a trading volume of 417,296 shares, compared to its average volume of 916,981. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock's fifty day moving average is $261.00 and its 200 day moving average is $206.63. The stock has a market capitalization of $13.14 billion, a price-to-earnings ratio of -56.74, a P/E/G ratio of 2.73 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.30.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the business posted $3.12 EPS. The company's revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares of the company's stock, valued at $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director owned 1,438 shares in the company, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 165,990 shares of company stock worth $42,606,388 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.